For instance, trastuzumab-resistant HER2-positive breast cancer was found associated with downregulated TGFBI, CXCL2, and SLC38A1, which was silenced by DNA hypermethylation (Palomeras et al., 2019). This evidence concerns the gene SLC38A1 and breast carcinoma.